MedTrace Logo

Participatory Evaluation (of) Aging (With) Rapamycin (for) Longevity Study

NCT04488601 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 129

Last updated 2024-01-24

No results posted yet for this study

Summary

This is a randomized, placebo-controlled trial into the safety and efficacy in reducing clinical measures of aging in an older adult population.

Conditions

  • Aging

Interventions

DRUG

Rapamycin

Rapamycin in 2 different dosage forms.

DRUG

Placebo

Placebo capsules

Sponsors & Collaborators

Principal Investigators

  • James Watson, MD · University of California, Los Angeles

  • Sajad Zalzala, MD · AgelessRx

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-01-01
Primary Completion
2023-12-30
Completion
2023-12-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04488601 on ClinicalTrials.gov